Lobe Sciences LtdCanadian Securities Exchange:LOBEView on OTCQB
- LAST PRICE0.0150
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0150/ 6
- Ask / Lots0.0150/ 30
- Open / Previous Close--- / 0.0150
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Time | Volume | LOBE |
|---|---|---|
| 10:11 ET | 91000 | 0.015 |
| 10:51 ET | 1000 | 0.015 |
| 11:18 ET | 8000 | 0.015 |
| 01:27 ET | 9000 | 0.015 |
| 03:46 ET | 32000 | 0.015 |
| 04:00 ET | 30000 | 0.015 |
Nov 18, 2024
Lobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin(TM), from 7:00PM ET on Monday Nov 18, 2024 by Dow Jones
7:00PM ET on Monday Nov 18, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Lobe Sciences Ltd | 3.4M | -0.4x | --- |
Genix Pharmaceuticals Corp | 2.4M | -0.7x | --- |
City View Green Holdings Inc | 1.8M | -1.6x | --- |
Craftport Cannabis Corp | 949.0K | -0.1x | --- |
Lords & Company Worldwide Holdings Inc | 1.2M | -0.5x | --- |
THC Biomed Intl Ltd | 3.3M | -0.9x | --- |
Company Information
Lobe Sciences Ltd. is a Canada-based biopharmaceutical company focused on developing medicines to treat diseases with unmet medical needs. The Company, through collaborations with partners, is engaged in research and development focused on treating chronic cluster headache (an orphan disease), refractive anxiety, and sickle cell disease. In addition, the Company is commercializing Altemia, for the treatment of patients diagnosed with Sickle Cell Disease. The Company is engaged in Phase 1 and Phase 2 activities in its drug portfolios. Its subsidiaries include Eleusian Biosciences Corp., Lobe Sciences Australia Pty Ltd., and Altemia & Company, LLC.
Contact Information
- Headquarters
- 1400-1199 West Hastings StreetVANCOUVER, BC, Canada V6E 3T5
- Phone
- 604-834-9499
- Fax
- 604-628-1249
Executives
- Chairman of the Board, Chief Executive Officer
- Frederick Sancilio
- Chief Financial Officer
- Brian Zasitko
- Director
- Rick Goulburn
- Director
- Harry Jacobson
- Director
- Wesley Ramjeet
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.4M |
|---|---|
Revenue (TTM) | $976.7K |
Shares Outstanding | 171.6M |
Lobe Sciences Ltd does not pay a dividend. | |
Beta | 2.07 |
EPS | $-0.03 |
Book Value | $0.00 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | 3.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -272.63% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
